News

Healthcare Executive Craig W. Abbott Named President & CEO of Saint Therese

SAINT LOUIS PARK, MN / ACCESSWIRE / April 22, 2022 / The Saint Therese Board of Directors has completed its…

2 years ago

CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 22, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a…

2 years ago

RxSight, Inc. to Present at the Bank of America Healthcare Conference

ALISO VIEJO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to…

2 years ago

Northwell Health Collaborates with Teladoc Health to Improve System Wide Virtual Care

Combined Teladoc Health and Microsoft capabilities to be leveraged for improved patient carePURCHASE, NY, April 22, 2022 (GLOBE NEWSWIRE) --…

2 years ago

Assertio Holdings, Inc. to Report First Quarter 2022 Financial Results After the Close of Markets on Monday, May 9, 2022

LAKE FOREST, Ill., April 22, 2022 (GLOBE NEWSWIRE) --  Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced…

2 years ago

IO Biotech Hosting Key Opinion Leader Webinar Series

Part 1: A New Way to Kill Tumors–IO102-IO103 Phase 3 Trial in Combination with Anti-PD-1 in Advanced Melanoma Thursday, April…

2 years ago

Stella Diagnostics Announces Leadership Changes: Dr. Joe Abdo Assumes a New Role as Chief Scientific Officer, and Director David Seaburg is Appointed Chief Executive Officer

SALT LAKE CITY, April 22, 2022 (GLOBE NEWSWIRE) -- Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient…

2 years ago

Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering

HOUSTON, April 22, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for…

2 years ago

Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA

Additional data collection and analysis reconfirms confidence in New Drug Application for TreosulfanNDA resubmission date consistent with previously announced timelineFDA…

2 years ago

SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

JERSEY CITY, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the pricing of its underwritten…

2 years ago